DK1103564T3 - Cancerantigener baseret på tumorsuppressorgen WT1-produkt - Google Patents

Cancerantigener baseret på tumorsuppressorgen WT1-produkt

Info

Publication number
DK1103564T3
DK1103564T3 DK99933205T DK99933205T DK1103564T3 DK 1103564 T3 DK1103564 T3 DK 1103564T3 DK 99933205 T DK99933205 T DK 99933205T DK 99933205 T DK99933205 T DK 99933205T DK 1103564 T3 DK1103564 T3 DK 1103564T3
Authority
DK
Denmark
Prior art keywords
product
tumor suppressor
suppressor gene
cancer antigens
antigens based
Prior art date
Application number
DK99933205T
Other languages
Danish (da)
English (en)
Inventor
Haruo Sugiyama
Yoshihiro Oka
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16714530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1103564(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Application granted granted Critical
Publication of DK1103564T3 publication Critical patent/DK1103564T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK99933205T 1998-07-31 1999-07-30 Cancerantigener baseret på tumorsuppressorgen WT1-produkt DK1103564T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21809398 1998-07-31
PCT/JP1999/004130 WO2000006602A1 (fr) 1998-07-31 1999-07-30 Antigenes contre le cancer a base d'un produit du gene suppresseur de tumeur wt1

Publications (1)

Publication Number Publication Date
DK1103564T3 true DK1103564T3 (da) 2009-05-11

Family

ID=16714530

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99933205T DK1103564T3 (da) 1998-07-31 1999-07-30 Cancerantigener baseret på tumorsuppressorgen WT1-produkt

Country Status (15)

Country Link
US (7) US7030212B1 (fr)
EP (3) EP2048160B1 (fr)
JP (2) JP4422903B2 (fr)
KR (1) KR100767554B1 (fr)
CN (4) CN1178956C (fr)
AT (1) ATE420112T1 (fr)
AU (1) AU4932199A (fr)
BR (1) BRPI9912663B8 (fr)
CA (1) CA2337743C (fr)
DE (1) DE69940264D1 (fr)
DK (1) DK1103564T3 (fr)
ES (1) ES2318898T3 (fr)
HK (4) HK1036073A1 (fr)
PT (1) PT1103564E (fr)
WO (1) WO2000006602A1 (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69723230T2 (de) 1996-01-17 2004-05-27 Imperial College Innovations Ltd. Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
MXPA01003344A (es) * 1998-09-30 2004-04-21 Corixa Corp Composiciones y metodos para inmunoterapia especifica de wt1.
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
WO2001025273A2 (fr) * 1999-10-04 2001-04-12 Corixa Corporation Compositions et methodes se rapportant a une immunotherapie specifique a wt1
EP1261711A2 (fr) * 2000-02-22 2002-12-04 Corixa Corporation Compositions et methodes destinees au diagnostic et a la therapie du mesotheliome malin
US20040097703A1 (en) * 2001-03-22 2004-05-20 Haruo Sugiyama Wt1 modified peptide
CA2451846A1 (fr) * 2001-06-29 2003-01-09 Chugai Seiyaku Kabushiki Kaisha Vaccin anticarcinogene contenant un antigene tumoral base sur un produit de gene wt1 suppresseur de tumeur et des liposomes cationiques
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
WO2003106682A1 (fr) 2002-06-12 2003-12-24 中外製薬株式会社 Peptide antigene du cancer a restriction hla-a24
US7342092B2 (en) 2002-09-12 2008-03-11 International Institute Of Cancer Immunology, Inc. Cancer antigen peptide formulations
DE60329201D1 (de) 2002-09-20 2009-10-22 Chugai Pharmaceutical Co Ltd Substituierte wt1-peptide
KR20120054644A (ko) * 2003-01-15 2012-05-30 추가이 세이야쿠 가부시키가이샤 이량체화 펩티드
EP2343083B1 (fr) 2003-06-27 2014-01-15 International Institute of Cancer Immunology, Inc. Procédé de diagnostic du cancer comprenant la mesure de la fréquence de cellules précurseurs des LTC de WTI
US20080070835A1 (en) 2003-11-05 2008-03-20 International Institute Of Cancer Immunology, Inc Hla-Dr-Binding Antigen Peptide Derived From Wt1
DK1731605T3 (da) * 2004-03-31 2010-05-25 Int Inst Cancer Immunology Inc Cancerantigenpeptider der er afledt af WT1
US8765687B2 (en) 2005-10-17 2014-07-01 Sloan Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
JP4394724B2 (ja) * 2005-11-30 2010-01-06 株式会社癌免疫研究所 新規ペプチド化合物
CA2645766A1 (fr) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Peptides wt1 immunogenes et leurs methodes d'utilisation
GB2440528A (en) * 2006-07-27 2008-02-06 Ist Superiore Sanita Antigen-antibody complexes
EP2127671B1 (fr) 2007-02-07 2016-09-14 Nec Corporation Agent therapeutique contre le cancer
PT2119778E (pt) 2007-02-27 2016-02-15 Int Inst Cancer Immunology Inc Método para ativação de célula t auxiliar e composição para utilização no método
KR101669279B1 (ko) 2007-03-05 2016-10-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
CA2881594C (fr) * 2007-12-05 2016-04-12 International Institute Of Cancer Immunology, Inc. Composition de vaccin contre le cancer
AR083295A1 (es) 2010-10-05 2013-02-13 Univ Osaka Metodo para activar celulas t auxiliares
CN105968191A (zh) 2011-06-28 2016-09-28 株式会社癌免疫研究所 肽癌抗原-特异性t细胞的受体基因
US9539299B2 (en) * 2011-10-27 2017-01-10 International Institute Of Cancer Immunology, Inc. Combination therapy with WT1 peptide vaccine and temozolomide
CN107880101B (zh) 2011-11-11 2021-12-21 弗雷德哈钦森癌症研究中心 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
JP6218175B2 (ja) * 2011-12-14 2017-10-25 国立大学法人高知大学 ヘルパーｔ細胞誘導性ポリペプチドの改変
EP3520810A3 (fr) 2012-01-13 2019-11-06 Memorial Sloan-Kettering Cancer Center Peptides wt1 immunogènes et ses utilisations
WO2014007266A1 (fr) 2012-07-02 2014-01-09 大日本住友製薬株式会社 Préparation transdermique de peptide antigénique associé au cancer
WO2014098012A1 (fr) 2012-12-17 2014-06-26 大塚製薬株式会社 Procédé pour activer des lymphocytes t auxiliaires
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
US9919037B2 (en) 2013-01-15 2018-03-20 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CN103961702B (zh) 2013-02-05 2019-04-09 日东电工株式会社 粘膜给予用wt1肽癌症疫苗组合物
EP2762152A1 (fr) 2013-02-05 2014-08-06 Nitto Denko Corporation Composition de vaccin contre le cancer peptidique WT1 pour administration transdermique
RU2687144C2 (ru) 2013-02-05 2019-05-07 Нитто Денко Корпорейшн Композиция противораковой вакцины, содержащей пептид wt1, для трансдермального введения
US10195258B2 (en) 2013-02-05 2019-02-05 Nitto Denko Corporation Tape preparation of WT1 peptide cancer vaccine for transdermal administration
RU2014102945A (ru) 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Вакцинная композиция
EP2762157A1 (fr) 2013-02-05 2014-08-06 Nitto Denko Corporation Vaccin pour administration par voie transdermique ou mucosale
CN103961697A (zh) 2013-02-05 2014-08-06 日东电工株式会社 粘膜给予用疫苗组合物
JP6440360B2 (ja) 2013-02-05 2018-12-19 日東電工株式会社 経皮投与用ワクチン組成物
ES2694328T3 (es) * 2013-03-12 2018-12-19 Sumitomo Dainippon Pharma Co., Ltd. Composición acuosa líquida
MY171854A (en) 2013-03-29 2019-11-05 Sumitomo Dainippon Pharma Co Ltd Wt1 antigen peptide conjugate vaccine
WO2014157704A1 (fr) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Vaccin conjugué utilisant une fonction de rognage de erap1
WO2016022400A1 (fr) 2014-08-04 2016-02-11 Fred Hutchinson Cancer Research Center Immunothérapie par cellules t spécifiques de la wt-1
US10471136B2 (en) 2014-09-27 2019-11-12 Sumitomo Dainippon Pharma Co., Ltd. Pharmaceutical composition for injection
EP3347028A1 (fr) * 2015-09-10 2018-07-18 Memorial Sloan Kettering Cancer Center Procédés de traitement du myélome multiple et de la leucémie à plasmocytes par thérapie par cellules t
CN116327903A (zh) 2015-11-20 2023-06-27 纪念斯隆凯特林癌症中心 用于治疗癌症的方法和组合物
IL260988B2 (en) * 2016-03-03 2023-03-01 Roussy Inst Gustave ptps-based vaccines against cancer
JP7209963B2 (ja) 2016-11-30 2023-01-23 住友ファーマ株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
EP3604325A4 (fr) 2017-03-30 2021-01-13 Sumitomo Dainippon Pharma Co., Ltd. Peptide wt1 d'antigène du cancer et corps conjugué peptidique le contenant
US20210338587A1 (en) 2018-09-28 2021-11-04 Sumitomo Dainippon Pharma Co., Ltd. Injectable composition
KR20210073540A (ko) * 2018-10-05 2021-06-18 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 양성 종양의 예방 또는 치료약
TW202045528A (zh) 2019-02-28 2020-12-16 日商大日本住友製藥股份有限公司 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
EP4017872A1 (fr) 2019-08-20 2022-06-29 Fred Hutchinson Cancer Center Immunothérapie par lymphocytes t, spécifique de wt-1
EP4085130A4 (fr) 2019-12-31 2024-04-10 Elixirgen Therapeutics Inc Administration transitoire basée sur la température d'acides nucléiques et de protéines à des cellules et des tissus
KR20230009426A (ko) 2020-05-12 2023-01-17 스미토모 파마 가부시키가이샤 암을 처치하기 위한 의약 조성물
MX2022013208A (es) * 2020-05-12 2022-11-14 Cue Biopharma Inc Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
AU2022327884A1 (en) 2021-08-12 2024-02-22 International Institute Of Cancer Immunology, Inc. Pharmaceutical composition and method for treatment or prevention of cancer

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6122018A (ja) 1984-07-06 1986-01-30 Green Cross Corp:The 癌免疫療法増強剤
JP2546254B2 (ja) 1987-02-23 1996-10-23 澁谷工業株式会社 ガス詰め充填装置
US5726288A (en) * 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
DE69033127T2 (de) 1989-11-13 1999-10-14 Massachusetts Inst Technology Lokalisation und charakterisierung des wilms-tumor-gens
US5731160A (en) * 1992-05-26 1998-03-24 Rijksuniversiteit Leiden Induction of antigen specific T-lymphocyte responses by stimulation with peptide loaded MHC class I molecules on antigen processing defective mammalian cell lines
JPH09506866A (ja) 1993-12-14 1997-07-08 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 医薬として活性のある物質の免疫療法のための放出制御
US5622835A (en) * 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
EP0772619B2 (fr) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Oligonucleotides immunomodulateurs
EP0841068B1 (fr) 1995-06-01 2006-07-12 Kishimoto, Tadamitsu Inhibiteur de la croissance de cellules leucemiques contenant des derives oligonucleotidiques antisens agissant contre le gene de la tumeur de wilms (wt1)
JP3904260B2 (ja) * 1995-06-01 2007-04-11 岸本 忠三 ウイルムス腫瘍遺伝子（ｗｔ１）に対するアンチセンスオリゴヌクレオチド誘導体を含んで成る白血病細胞増殖阻害剤
AU715944B2 (en) 1995-09-19 2000-02-10 Bayer Cropscience Aktiengesellschaft Plants which synthesize a modified starch, process for the production thereof and modified starch
JP3060287B2 (ja) 1995-10-09 2000-07-10 参天製薬株式会社 アパファントを主薬とする水性点眼剤
JPH09191635A (ja) 1996-01-05 1997-07-22 Toshio Aida モータ
DE69723230T2 (de) 1996-01-17 2004-05-27 Imperial College Innovations Ltd. Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US20030092656A1 (en) 1997-07-16 2003-05-15 Haruo Sugiyama Therapeutic agents for treatment of solid tumors comprising an expression-inhibiting sustance against Wilms' tumor gene (WT1)
JP4789095B2 (ja) 1997-07-16 2011-10-05 治夫 杉山 ウイルムス腫瘍遺伝子（ｗｔ１）に対する発現阻害物質を含んで成る固形腫瘍治療剤
US5985264A (en) 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
MXPA01003344A (es) 1998-09-30 2004-04-21 Corixa Corp Composiciones y metodos para inmunoterapia especifica de wt1.
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US20030215458A1 (en) 1998-09-30 2003-11-20 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
TR200102024T2 (tr) 1999-01-12 2001-12-21 Smithkline Beecham Biologicals S.A. Yeni tedavi.
SI1031346T1 (en) 1999-01-27 2002-08-31 Idea Ag Noninvasive vaccination through the skin
CA2313392A1 (fr) 1999-07-22 2001-01-22 Sumitomo Pharmaceuticals Company, Limited Agent pour l'induction de cellules t specifiques de l'antigene
JP2001089389A (ja) 1999-07-22 2001-04-03 Sumitomo Pharmaceut Co Ltd 抗原特異的ｔ細胞の誘導剤
EP1261711A2 (fr) 2000-02-22 2002-12-04 Corixa Corporation Compositions et methodes destinees au diagnostic et a la therapie du mesotheliome malin
US20040097703A1 (en) 2001-03-22 2004-05-20 Haruo Sugiyama Wt1 modified peptide
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
US20050002951A1 (en) 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
WO2003106682A1 (fr) * 2002-06-12 2003-12-24 中外製薬株式会社 Peptide antigene du cancer a restriction hla-a24
US7342092B2 (en) * 2002-09-12 2008-03-11 International Institute Of Cancer Immunology, Inc. Cancer antigen peptide formulations
DE60329201D1 (de) * 2002-09-20 2009-10-22 Chugai Pharmaceutical Co Ltd Substituierte wt1-peptide
KR20120054644A (ko) * 2003-01-15 2012-05-30 추가이 세이야쿠 가부시키가이샤 이량체화 펩티드
EP2343083B1 (fr) * 2003-06-27 2014-01-15 International Institute of Cancer Immunology, Inc. Procédé de diagnostic du cancer comprenant la mesure de la fréquence de cellules précurseurs des LTC de WTI
US20080070835A1 (en) 2003-11-05 2008-03-20 International Institute Of Cancer Immunology, Inc Hla-Dr-Binding Antigen Peptide Derived From Wt1
DK1731605T3 (da) 2004-03-31 2010-05-25 Int Inst Cancer Immunology Inc Cancerantigenpeptider der er afledt af WT1

Also Published As

Publication number Publication date
US7390871B2 (en) 2008-06-24
US20090143291A1 (en) 2009-06-04
ATE420112T1 (de) 2009-01-15
HK1130069A1 (en) 2009-12-18
US20050266014A1 (en) 2005-12-01
KR20010072112A (ko) 2001-07-31
US7030212B1 (en) 2006-04-18
US20160243209A1 (en) 2016-08-25
US20090281043A1 (en) 2009-11-12
US7517950B2 (en) 2009-04-14
CN1762490A (zh) 2006-04-26
JP5230579B2 (ja) 2013-07-10
KR100767554B1 (ko) 2007-10-17
JP4422903B2 (ja) 2010-03-03
CN1560078A (zh) 2005-01-05
CA2337743C (fr) 2015-07-07
HK1038929A1 (en) 2002-04-04
US20060093615A1 (en) 2006-05-04
EP2048160B1 (fr) 2015-01-07
EP2280031B1 (fr) 2015-04-15
CN1314916A (zh) 2001-09-26
DE69940264D1 (de) 2009-02-26
US7608685B1 (en) 2009-10-27
JP2010059172A (ja) 2010-03-18
US7807792B2 (en) 2010-10-05
BRPI9912663A (pt) 2001-05-02
EP1103564A1 (fr) 2001-05-30
HK1153761A1 (en) 2012-04-05
CN102198266A (zh) 2011-09-28
AU4932199A (en) 2000-02-21
EP1103564A4 (fr) 2005-02-02
BRPI9912663B1 (pt) 2011-05-31
US9403886B2 (en) 2016-08-02
HK1038929B (zh) 2005-05-06
CN100560130C (zh) 2009-11-18
WO2000006602A1 (fr) 2000-02-10
BRPI9912663B8 (pt) 2021-07-06
ES2318898T3 (es) 2009-05-01
EP1103564B1 (fr) 2009-01-07
CA2337743A1 (fr) 2000-02-10
CN1560078B (zh) 2011-06-22
EP2048160A1 (fr) 2009-04-15
CN1178956C (zh) 2004-12-08
HK1036073A1 (en) 2001-12-21
EP2280031A1 (fr) 2011-02-02
PT1103564E (pt) 2009-03-13

Similar Documents

Publication Publication Date Title
DK1103564T3 (da) Cancerantigener baseret på tumorsuppressorgen WT1-produkt
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1113185T1 (el) Μεθοδοι συνενωσης αποδεκτη πεπτιδιου
CY1118901T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY2016021I1 (el) Στελεχη ιων για την ογκολυτικη θεραπεια του καρκινου
BRPI0417107A (pt) fragmento de anticorpo, métodos de preparação do fragmento de anticorpo, ácido nucléico isolado, composições, célula hospedeira e métodos de fabricação e de geração de fragmento de anticorpo
ATE315088T1 (de) Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
CY1112735T1 (el) Πολυπεπτιδια δυναμενα εκμαιευσης μιας ανοσιακης αντιδρασης εναντι του καρκινου
UA84284C2 (ru) Способы лечения, профилактики и диагностики инфекции helicobacter cerdo
DK1536006T3 (da) Cancerantigener og anvendelse deraf
FR2744455B1 (fr) Nouvelles sequences d'acides nucleiques de la famille des facteurs suppresseurs de tumeurs, produits d'expression correspondants et leurs applications
FI970071A0 (fi) Eristetty nukleiinihapposekvenssi, joka koodaa HLA-A2:n esittämää tuumorihyljintäantigeeniä
PL372769A1 (en) Cyanoguanidine prodrugs
ES2502366T3 (es) Inducción de inmunidad tumoral por variantes de proteína de unión a folato
DE69402201D1 (de) Phosphorhaltiges, metallurgisches silizium zur herstellung von organohalosilanen
DK1005532T3 (da) Isolerede nukleinsyremolekyler kodende for SSX familiemedlemmer og anvendelser deraf
DE60015058D1 (de) Kombinationsimpfstoff zur steigerung der Immunität gegen Brucellose
IT1286307B1 (it) Virus mixomatoso ricombinante, suo impiego per la produzione di un vaccino e relativo vaccino.
LV12722A (lv) Prv-1 gene and the use thereof
CY1112454T1 (el) Ανασυνδυασμενη καρβοξυπεπτιδαση β
IT1256078B (it) Ligandi kit solubili
ITVI940084A0 (it) Impilatore per prodotti laminari flessibili, particolarmente per pellied affini.
SG166673A1 (en) Immunostimulatory nucleic acids